Mold-Tek Packaging (533080) Q4 25/26 earnings summary

Executive summary

• Achieved strong financial performance in FY26 with revenue up 13.48%, EBITDA up over 20%, and PAT up 20.35% year-over-year, driven by improved capacity utilization, consolidation of Hyderabad units, and operational efficiencies.

• Pharma packaging segment grew over 200% for the year, surpassing targets, with plans to expand product range and capacity.

• Paints business delivered double-digit growth, offsetting declines in lubricants; food and FMCG grew over 15%, and Q-Pack by over 25%.

• Operational efficiency improved through R&D, automation, and strategic partnerships, including AI-based inspection and a UK collaboration.

• Sales volumes increased by 11.39% year-over-year, with notable growth in Pharma Packs (208.96%), FMCG Packs (18.04%), Q-Packs (25.82%), and Paint Packs (14.41%).

Financial highlights

• FY26 revenue reached INR 886.60 crore, up from INR 781.32 crore in FY25 (13.48% growth).

• EBITDA for FY26 was INR 173.66 crore, up over 20% year-over-year; PAT was INR 72.87 crore, up 20.35%.

• EBITDA per kg improved to INR 40.74 from INR 37.60 last year, an 8.4% increase.

• Q4FY26 revenue was INR 237.86 crore, EBITDA INR 48.10 crore, and PAT INR 20.64 crore, all showing double-digit growth over Q4FY25.

• Net cash from operating activities for FY26 was INR 12,536.64 lakhs.

Outlook and guidance

• Targeting INR 50–55 crore pharma sales in FY27, aiming for 50% growth.

• Projected 10–13% volume growth and 13–15% value growth for FY27, with turnover expected to exceed INR 1,000 crore.

• EBITDA per kg expected to reach INR 42.5–43 in FY27, with potential for 44–45 in FY28.

• EBITDA guidance for FY27 is INR 210 crore, up from INR 173 crore.

• Plans to expand pharma packaging capacity and product range, with full benefits from Hyderabad consolidation anticipated.